Why "Wait and See" Isn't an Option
It’s happening…are you ready? As we are coming to the end of Q1 2019, the FDA recently finalized two guidance documents regarding Regenerative Medicine (as of Feb 15, 2019). There is no doubt FDA...
Mon, Mar 11, 2019 | By Lindsay Belcher, Business Development Director - Northeast, Cryoport
It’s happening…are you ready? As we are coming to the end of Q1 2019, the FDA recently finalized two guidance documents regarding Regenerative Medicine (as of Feb 15, 2019). There is no doubt FDA...
Thu, Mar 07, 2019 | By Kirk Randall, Senior Director, Business Development, Cryoport
In choosing a logistics provider and important factor is to find someone who is carrier agnostic. So what does that mean? It means the solution provider is able to use, and track the performance of,...
Mon, Feb 25, 2019 | By Cryoport Team
Precision medicine requires end-to-end traceability: everything from chain of custody, to chain of condition, to chain of identity. But the fragility of regenerative medicine therapies – and the need...
Wed, Feb 20, 2019 | By Sue Blecman, Vice President - Global Strategic Business Development, Cryoport
We’re often asked by our clients what packaging and containment materials should be used to help prevent damage to their shipment contents.In reviewing shipper “packouts” with clients for upcoming...
Mon, Feb 11, 2019 | By Tom Heinzen, VP, Corporate Development & Investor Relations, Cryoport
On January 15th FDA Commissioner Scott Gottlieb, M.D. and Peter Marks, M.D., Ph.D, Director of the Center for Biologics Evaluation and Research released a public statement which outlined new policies...
Thu, Jan 19, 2017 | By Mark W. Sawicki, Ph.D., Chief Commercial Officer, Cryoport
Providing $6.3 billion in funding for medical innovation to expedite the discovery, development and delivery of new treatments and cures, the 21st Century Cures Act (Cures) received overwhelming...
Mon, Feb 29, 2016 | By Robert Hariri, M.D., Ph.D., Board of Directors, Cryoport
During the 2016 Super Bowl, New York-Presbyterian Hospital aired a 60-second advertisement, titled “Unmasking a Killer,” highlighting the hospital’s advanced cancer research and treatment. The ad...
Americas • EMEA • APAC
Sales • +1 949.470.2300 | Support • +1 949.470.2305
©2023 Cryoport Systems, LLC. All rights reserved.
A Leap Forward in Standardizing the Regenerative Medicine Supply Chain – What the New ISO 21973 Guidance Means for Cell and Gene Therapy Developers
Cryoport® is a trademark of Cryoport, Inc. and used with permission by Cryoport Systems, LLC